Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GTUOW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HuM25-mcMMAF-E2
|
|||||
| Synonyms |
HuM25 mcMMAF-E2; huM25 mcMMAF-E2
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
HuM25
|
Antibody Info | ||||
| Antigen Name |
Leucine-rich repeat-containing protein 15 (LRRC15)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin F
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Maleimido-caproyl
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
McMMAF
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
0.01 - 0.10
|
nM
|
HCT 116 cells
|
Colon carcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 0.00% | Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-MCMMAF-E2 (12 mg/kg) was demonstrated in PANC-1 xenografts.
|
||||
| In Vivo Model | PANC-1 CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | PANC-1 cells | CVCL_0480 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 8.47% (Day 11) | High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-MCMMAF-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.01 nM - 0.10 nM | Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.